|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
1961
|
|
gptkbp:ATCCode
|
N06AA09
|
|
gptkbp:brand
|
gptkb:Amitrol
gptkb:Elavil
gptkb:Endep
gptkb:Laroxyl
gptkb:Tryptanol
|
|
gptkbp:CASNumber
|
50-48-6
|
|
gptkbp:category
|
gptkb:tricyclic_antidepressants
WHO Essential Medicines
|
|
gptkbp:chemicalFormula
|
C20H23N
|
|
gptkbp:contraindication
|
severe liver disease
recent myocardial infarction
concurrent MAOI use
|
|
gptkbp:developedBy
|
gptkb:Merck
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:eliminationHalfLife
|
10–50 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
amitriptyline
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
anticholinergic
alpha-1 adrenergic antagonist
antihistaminic
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
death
coma
seizures
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
2160
DB00321
|
|
gptkbp:riskOfOverdose
|
high
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
gptkb:orthostatic_hypotension
constipation
blurred vision
weight gain
drowsiness
dry mouth
urinary retention
sexual dysfunction
|
|
gptkbp:UNII
|
2ZCN55GSZ1
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
peripheral neuropathy
chronic pain
insomnia
anxiety disorders
fibromyalgia
irritable bowel syndrome
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|